Please login to the form below

Not currently logged in
Email:
Password:

parkinson's disease

This page shows the latest parkinson's disease news and features for those working in and with pharma, biotech and healthcare.

Biogen pays Denali $1bn upfront for Parkinsons disease programme

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors. Biogen has signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for ... Mutations in the LRRK2 gene, a regulator of

Latest news

More from news
Approximately 31 fully matching, plus 194 partially matching documents found.

Latest Intelligence

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinsons disease

    signalling a forlorn future for the Parkinson’s disease community. ... In Europe, the burden is immense, with the European Parkinson’s Disease Association, which represents 45 member groups, estimating an annual cost of 13.9bn to care for the 1.2

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Now, interest is growing in a largely-untapped approach to targeting disease-associated proteins, particularly those that for many years have been considered ‘undruggable’. ... C4 also has a collaboration in place with Biogen focusing on neurological

  • Case study: What we're made of Case study: What we're made of

    If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple

  • Novel endpoints in the digital age Novel endpoints in the digital age

    In addition to being limited in terms of their objectivity, these measures also may capture only brief ‘snapshots’ of the participant’s functionality and/or disease burden at a given point ... Tenaerts cited a CTTI case study outlining the case for

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Forging innovative solutions by merging art and science

    She studied neuroscience at the University of Toronto, worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis, and was also a therapist in private ... practice. Ariel’s uncommon

  • The ALS patient journey

    Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ... That will be the start of ALS, but your doctor will want to rule out other things, for example, Parkinson’s disease or multiple sclerosis.

  • The growing clinical importance of patient-reported outcomes (PROs)

    For example, in a clinical trial conducted for Parkinson’s disease (PD), the effect of using Levodopa-sparing treatments on QoL was tested. ... overall QoL, as measured on a disease-specific PRO, the Parkinson’s Disease Questionnaire.

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • Leading Edge expands their senior medical writing team

    of Oxford, where she studied the use of stem cells as an in-vitro model of Parkinson’s disease.

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics